Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Breast Neoplasms 22Neoplasm Metastasis 15Carcinoma, Non-Small-Cell Lung 7Glioblastoma 6Colorectal Neoplasms 5Triple Negative Breast Neoplasms 4Recurrence 4Ovarian Neoplasms 4Lymphoma, Mantle-Cell 4Lymphoma, Follicular 4Endometrial Neoplasms 4Brain Neoplasms 4Squamous Cell Carcinoma of Head and Neck 3Prostatic Neoplasms 3Pancreatic Neoplasms 3Neoplasms 3Lymphoma, Large B-Cell, Diffuse 3Lung Neoplasms 3Hereditary Sensory and Autonomic Neuropathies 3Head and Neck Neoplasms 3Solid Tumors 2Melanoma 2Lymphoma 2Leukemia, Myeloid, Acute 2Leukemia, Lymphocytic, Chronic, B-Cell 2Esophageal Neoplasms 2Waldenstrom Macroglobulinemia 1Unspecified Adult Solid Tumor, Protocol Specific 1Treatment for Metastatic or Locally Advanced Cervical Cancer 1Tongue Neoplasms 1

Interventions

Rituximab 99Cyclophosphamide 63fludarabine phosphate 54Peripheral Blood Stem Cell Transplantation 52Mycophenolic Acid 33Bortezomib 33Whole-Body Irradiation 32ibrutinib 29Dexamethasone 27Tacrolimus 25Cyclosporine 25Etoposide 22Busulfan 22Melphalan 20Filgrastim 20Methotrexate 18Lenalidomide 18Antilymphocyte Serum 18Radiotherapy 16zanubrutinib 14Bendamustine Hydrochloride 14Sirolimus 13Calcium Dobesilate 11Everolimus 10venetoclax 9ibritumomab tiuxetan 9Prednisone 9Cyclosporins 9idelalisib 8Indium 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Waldenstrom Macroglobulinemia × NVP-BKM120 × Clear all
NCT02049541 2022-06-30

Study of BKM120 & Rituximab in Patients With Relapsed or Refractory Indolent B-Cell Lymphoma

Ohio State University Comprehensive Cancer Center

Phase 1 Completed
18 enrolled
Lymphoid

Lymphoma, Follicular, Waldenstrom Macroglobulinemia, Lymphoma, B-Cell, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡